Lenvakast 4 mg (Lenvatinib)

Description

Lenvakast 4 mg (Lenvatinib) is the anti-cancer agent employed for managing different types of cancer. Lenvakast 4 mg (Lenvatinib) is indicated against Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) and Differentiated Thyroid Cancer (DTC). Lenvakast 4 mg (Lenvatinib) is primarily taken at the same time every day, however, the dosing differs based on the type of cancer. The drug is consumed orally either with or without food.

The table below shows different dosing patterns of Lenvakast 4 mg (Lenvatinib) based on the type of cancer and conditions associated with it.

Clinically, Lenvakast 4 mg (Lenvatinib) is an inhibitor drug which stops growth, proliferation and aggravation of cancer by rendering adept anti-tumor activities. It takes around 1 to 4 hours to completely absorb in the system. Subsequently, it binds very efficiently (98% to 99% of binding efficacy) with cancer cells to carry its anti-tumor actions. Once the actions are done, it takes around 28 hours to eliminate 50% of the drug from the system.

Warnings and Precautions associated with Lenvakast 4 mg (Lenvatinib):

The healthcare provider should be informed about certain conditions before administering Lenvakast 4 mg (Lenvatinib). The conditions include,

• High blood pressure (Hypertension)
• Heart problems
• History of blood clots, stroke, heart attack, or changes in vision
• Kidney or liver complications
• Tear in the stomach or intestines (Perforation)
• Atypical connections between two sections of the gastrointestinal tract (Fistula)
• Low levels of calcium in the blood (Hypocalcemia)
• Severe bleeding through different regions of the body
• Problems in healing the wounds
• Increased amounts of protein in the urine (Proteinuria)

Side-effects associated with Lenvakast 4 mg (Lenvatinib):

Diarrhea is the most common side-effect of the drug. However, there are certain common side-effects of Lenvakast 4 mg (Lenvatinib) based on the type of cancer. Among them, tiredness, vomiting, nausea, pain in the stomach region (abdomen), joints and muscles, loss of weight and appetite, are the most common ones in all three types of cancers.

Note: Lenvakast 4 mg (Lenvatinib) might show other side-effects as well. Refer your healthcare provider for more updates regarding the drug.

Lenvakast 4 mg (Lenvatinib) is also available in these countries: (South East Asia, South America, Eastern Europe, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic and Slovenia.)